(TEVA) Teva Pharma Industries - Ratings and Ratios
Generic Drugs, Corticosteroid Inhaler, Migraine Prevention, Multiple Sclerosis
TEVA EPS (Earnings per Share)
TEVA Revenue
Description: TEVA Teva Pharma Industries
Teva Pharmaceutical Industries Ltd is a global pharmaceutical company with a diverse portfolio of generic and branded medicines, as well as biopharmaceutical products. The company operates in multiple therapeutic areas, including CNS, respiratory, and oncology, and offers a range of products, including injectables, inhalants, and oral dosage forms.
From a product perspective, Teva has a number of notable brands, including COPAXONE, AJOVY, and AUSTEDO, which are used to treat conditions such as multiple sclerosis, migraine, and movement disorders. The company also has a significant presence in the generic medicines market, with a wide range of products available in various dosage forms.
In terms of key performance indicators (KPIs), Tevas market capitalization is approximately $19 billion, with a forward P/E ratio of 6.27. The companys return on equity (ROE) is currently negative, at -21.36%, indicating that it has faced challenges in generating profits for shareholders. To improve this metric, Teva may need to focus on optimizing its product portfolio, reducing costs, and improving operational efficiency.
From a strategic perspective, Teva has established partnerships with several companies, including MedinCell S.A., Sanofi, and Alvotech, which may help to drive growth and innovation. The companys out-licensing platform also provides an opportunity to generate additional revenue through partnerships with other pharmaceutical companies.
To evaluate Tevas investment potential, it is essential to analyze its financial performance, including revenue growth, profit margins, and cash flow generation. Additionally, assessing the companys pipeline of new products and its competitive position in the market will be crucial in determining its long-term prospects.
TEVA Stock Overview
| Market Cap in USD | 22,522m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1990-03-26 |
TEVA Stock Ratings
| Growth Rating | 42.0% |
| Fundamental | 54.7% |
| Dividend Rating | 18.5% |
| Return 12m vs S&P 500 | -12.9% |
| Analyst Rating | 4.45 of 5 |
TEVA Dividends
Currently no dividends paidTEVA Growth Ratios
| Growth Correlation 3m | 58.4% |
| Growth Correlation 12m | -25.3% |
| Growth Correlation 5y | 59.2% |
| CAGR 5y | 30.75% |
| CAGR/Max DD 3y | 0.70 |
| CAGR/Mean DD 3y | 2.85 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | 0.00 |
| Beta | 0.321 |
| Volatility | 50.24% |
| Current Volume | 11220.8k |
| Average Volume 20d | 9599.6k |
| Stop Loss | 18 (-3.6%) |
| Signal | -0.30 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-158.0m TTM) > 0 and > 6% of Revenue (6% = 997.7m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.56% (prev -8.62%; Δ 13.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 1.39b > Net Income -158.0m (YES >=105%, WARN >=100%) |
| Net Debt (15.36b) to EBITDA (1.90b) ratio: 8.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.16b) change vs 12m ago 2.47% (target <= -2.0% for YES) |
| Gross Margin 49.60% (prev 49.52%; Δ 0.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 40.82% (prev 39.43%; Δ 1.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.56 (EBITDA TTM 1.90b / Interest Expense TTM 1.55b) >= 6 (WARN >= 3) |
Altman Z'' -1.46
| (A) 0.02 = (Total Current Assets 12.62b - Total Current Liabilities 11.86b) / Total Assets 40.13b |
| (B) -0.37 = Retained Earnings (Balance) -14.68b / Total Assets 40.13b |
| (C) 0.02 = EBIT TTM 875.0m / Avg Total Assets 40.73b |
| (D) -0.51 = Book Value of Equity -17.05b / Total Liabilities 33.30b |
| Total Rating: -1.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.66
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 2.62% = 1.31 |
| 3. FCF Margin 5.93% = 1.48 |
| 4. Debt/Equity 2.52 = -0.03 |
| 5. Debt/Ebitda 9.08 = -2.50 |
| 6. ROIC - WACC (= 3.18)% = 3.98 |
| 7. RoE -2.58% = -0.43 |
| 8. Rev. Trend 62.14% = 4.66 |
| 9. EPS Trend -16.07% = -0.80 |
What is the price of TEVA shares?
Over the past week, the price has changed by -5.08%, over one month by +3.43%, over three months by +6.74% and over the past year by +3.38%.
Is Teva Pharma Industries a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TEVA is around 19.54 USD . This means that TEVA is currently overvalued and has a potential downside of 4.6%.
Is TEVA a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TEVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.6 | 26.1% |
| Analysts Target Price | 23.6 | 26.1% |
| ValueRay Target Price | 21.5 | 15.2% |
Last update: 2025-09-12 04:46
TEVA Fundamental Data Overview
CCE Cash And Equivalents = 2.16b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 6.8918
P/S = 1.3544
P/B = 3.2884
P/EG = 1.2934
Beta = 0.725
Revenue TTM = 16.63b USD
EBIT TTM = 875.0m USD
EBITDA TTM = 1.90b USD
Long Term Debt = 16.76b USD (from longTermDebt, last quarter)
Short Term Debt = 464.0m USD (from shortTermDebt, last quarter)
Debt = 17.23b USD (Calculated: Short Term 464.0m + Long Term 16.76b)
Net Debt = 15.36b USD (from netDebt column, last quarter)
Enterprise Value = 37.59b USD (22.52b + Debt 17.23b - CCE 2.16b)
Interest Coverage Ratio = 0.56 (Ebit TTM 875.0m / Interest Expense TTM 1.55b)
FCF Yield = 2.62% (FCF TTM 986.0m / Enterprise Value 37.59b)
FCF Margin = 5.93% (FCF TTM 986.0m / Revenue TTM 16.63b)
Net Margin = -0.95% (Net Income TTM -158.0m / Revenue TTM 16.63b)
Gross Margin = 49.60% ((Revenue TTM 16.63b - Cost of Revenue TTM 8.38b) / Revenue TTM)
Tobins Q-Ratio = -2.20 (set to none) (Enterprise Value 37.59b / Book Value Of Equity -17.05b)
Interest Expense / Debt = 1.68% (Interest Expense 288.9m / Debt 17.23b)
Taxrate = -37.46% (set to none) (-78.0m / 208.2m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.06 (Total Current Assets 12.62b / Total Current Liabilities 11.86b)
Debt / Equity = 2.52 (Debt 17.23b / last Quarter total Stockholder Equity 6.83b)
Debt / EBITDA = 9.08 (Net Debt 15.36b / EBITDA 1.90b)
Debt / FCF = 17.47 (Debt 17.23b / FCF TTM 986.0m)
Total Stockholder Equity = 6.13b (last 4 quarters mean)
RoA = -0.39% (Net Income -158.0m, Total Assets 40.13b )
RoE = -2.58% (Net Income TTM -158.0m / Total Stockholder Equity 6.13b)
RoCE = 3.82% (Ebit 875.0m / (Equity 6.13b + L.T.Debt 16.76b))
RoIC = 3.18% (Ebit 875.0m / (Assets 40.13b - Current Assets 12.62b))
WACC = unknown (E(22.52b)/V(39.75b) * Re(7.20%)) + (D(17.23b)/V(39.75b) * Rd(1.68%) * (1-Tc(none)))
Shares Correlation 3-Years: 66.68 | Cagr: 0.34%
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈1.11b ; Y1≈1.37b ; Y5≈2.33b
Fair Price DCF = 34.58 (DCF Value 39.67b / Shares Outstanding 1.15b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -16.07 | EPS CAGR: 4.16% | SUE: 0.10 | # QB: 0
Revenue Correlation: 62.14 | Revenue CAGR: 5.60% | SUE: N/A | # QB: None
Additional Sources for TEVA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle